


# Fluorine-18 molecular imaging



## DOPAVIEW / PADOVIEW

Advanced Accelerator Applications brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog

Neurology, Oncology

### SmPC

### France

- [Notice of transparency \(PDF 0.5 MB\)](#)
- [Summary of product characteristics \(PDF 0.4 MB\)](#)
- [User information \(PDF 0.3 MB\)](#)

### Germany

- [Technical information \(PDF 0.2 MB\)](#)
- [User Information \(PDF 0.2 MB\)](#)

### Italy

- [Summary of product characteristics \(PDF 0.2 MB\)](#)

### Portugal

- [Summary of product characteristics \(PDF 0.3 MB\)](#)

### Spain

- [Technical information](#)

### Switzerland

- [Professional information French \(PDF 0.1 MB\)](#)
  - [Professional information German \(PDF 0.1 MB\)](#)
  - [Professional information Italian \(PDF 0.1 MB\)](#)
- 



## **FLUOROCHOL / AAACHOLINE / CHOLSCAN**

Advanced Accelerator Applications brand names for [18F]-choline (FCH)

Oncology

**SmPC**

**France**

- [Notice of transparency \(PDF 0.4 MB\)](#)
- [Summary of product characteristics \(PDF 0.2 MB\)](#)
- [User information \(PDF 0.2 MB\)](#)

**Germany**

- [Technical information \(PDF 0.2 MB\)](#)
- [User Information \(PDF 0.2 MB\)](#)

**Italy**

- [Summary of product characteristics \(PDF 0.2 MB\)](#)

**Portugal**

- [Summary of product characteristics \(PDF 0.3 MB\)](#)

**Spain**

- [Technical information](#)

**Switzerland**

- [Professional information French \(PDF 0.1 MB\)](#)
- [Professional information German \(PDF 0.1 MB\)](#)

- [Professional information Italian \(PDF 0.2 MB\)](#)
- 



## **GLUSCAN / BARNASCAN**

Advanced Accelerator Applications brand names for FDG (most widely used PET tracer)

Oncology, Cardiology, Neurology, Infectious and inflammatory diseases

### **SmPC**

#### **France**

- [Notice of transparency \(PDF 0.1 MB\)](#)
- [Summary of product characteristics \(PDF 0.3 MB\)](#)
- [User information \(PDF 0.2 MB\)](#)

#### **Germany**

- [Technical information \(PDF 0.1 MB\)](#)
- [User Information \(PDF 0.2 MB\)](#)

#### **Italy**

- [Summary of product characteristics \(PDF 0.3 MB\)](#)

#### **Portugal**

- [Summary of product characteristics \(PDF 0.3 MB\)](#)
- [User information \(PDF 0.2 MB\)](#)

#### **Spain**

- [Barnascan technical information](#)
- [Gluscan technical information](#)

#### **Switzerland**

- [Professional information on medicines for human use French \(PDF 0.2 MB\)](#)
- [Professional information on medicines for human use German \(PDF 0.2 MB\)](#)
- [Professional information on medicines for human use Italian \(PDF 0.2 MB\)](#)

**List of links present in page**

1. <https://www.adacap.com/our-products/fluorine-18-molecular-imaging>
2. [https://www.adacap.com/sites/novartis\\_adacap/files/CT\\_DOPAVIEW.pdf](https://www.adacap.com/sites/novartis_adacap/files/CT_DOPAVIEW.pdf)
3. [https://www.adacap.com/sites/novartis\\_adacap/files/2023\\_01\\_19\\_Master-SPC\\_Dopaview\\_FR.pdf](https://www.adacap.com/sites/novartis_adacap/files/2023_01_19_Master-SPC_Dopaview_FR.pdf)
4. [https://www.adacap.com/sites/novartis\\_adacap/files/2023\\_01\\_19\\_Master-PIL\\_Dopaview\\_FR.pdf](https://www.adacap.com/sites/novartis_adacap/files/2023_01_19_Master-PIL_Dopaview_FR.pdf)
5. [https://www.adacap.com/sites/novartis\\_adacap/files/Dopaview-FI-Dezember-2022.pdf](https://www.adacap.com/sites/novartis_adacap/files/Dopaview-FI-Dezember-2022.pdf)
6. [https://www.adacap.com/sites/novartis\\_adacap/files/Dopaview-GI-Dezember-2022-1.pdf](https://www.adacap.com/sites/novartis_adacap/files/Dopaview-GI-Dezember-2022-1.pdf)
7. [https://www.adacap.com/sites/novartis\\_adacap/files/PADOVIEW\\_RCP\\_JAN23-1.pdf](https://www.adacap.com/sites/novartis_adacap/files/PADOVIEW_RCP_JAN23-1.pdf)
8. [https://www.adacap.com/sites/novartis\\_adacap/files/RCM\\_Dopaview.pdf](https://www.adacap.com/sites/novartis_adacap/files/RCM_Dopaview.pdf)
9. [https://cima.aemps.es/cima/dochtml/ft/83007/FT\\_83007.html](https://cima.aemps.es/cima/dochtml/ft/83007/FT_83007.html)
10. [https://www.adacap.com/sites/novartis\\_adacap/files/AAADopaview\\_CH\\_RCP\\_FR\\_AIPS\\_190630.pdf](https://www.adacap.com/sites/novartis_adacap/files/AAADopaview_CH_RCP_FR_AIPS_190630.pdf)
11. [https://www.adacap.com/sites/novartis\\_adacap/files/AAADopaview\\_CH\\_RCP\\_DE\\_AIPS\\_190630.pdf](https://www.adacap.com/sites/novartis_adacap/files/AAADopaview_CH_RCP_DE_AIPS_190630.pdf)
12. [https://www.adacap.com/sites/novartis\\_adacap/files/AAADopaview\\_CH\\_RCP\\_IT\\_AIPS\\_190630.pdf](https://www.adacap.com/sites/novartis_adacap/files/AAADopaview_CH_RCP_IT_AIPS_190630.pdf)
13. [https://www.adacap.com/sites/novartis\\_adacap/files/CT\\_FLUOROCHOL.pdf](https://www.adacap.com/sites/novartis_adacap/files/CT_FLUOROCHOL.pdf)
14. [https://www.adacap.com/sites/novartis\\_adacap/files/SPC-Fluorochol-Feb-2024.pdf](https://www.adacap.com/sites/novartis_adacap/files/SPC-Fluorochol-Feb-2024.pdf)
15. [https://www.adacap.com/sites/novartis\\_adacap/files/PIL-Fluorochol-Feb-2024.pdf](https://www.adacap.com/sites/novartis_adacap/files/PIL-Fluorochol-Feb-2024.pdf)
16. [https://www.adacap.com/sites/novartis\\_adacap/files/Fluorochol-FI-Dezember-2022.pdf](https://www.adacap.com/sites/novartis_adacap/files/Fluorochol-FI-Dezember-2022.pdf)
17. [https://www.adacap.com/sites/novartis\\_adacap/files/Fluorochol-GI-Dezember-2022-1.pdf](https://www.adacap.com/sites/novartis_adacap/files/Fluorochol-GI-Dezember-2022-1.pdf)
18. [https://www.adacap.com/sites/novartis\\_adacap/files/CHOLSCAN\\_RCP\\_JAN23-2.pdf](https://www.adacap.com/sites/novartis_adacap/files/CHOLSCAN_RCP_JAN23-2.pdf)
19. [https://www.adacap.com/sites/novartis\\_adacap/files/RCM\\_Cholview.pdf](https://www.adacap.com/sites/novartis_adacap/files/RCM_Cholview.pdf)
20. [https://cima.aemps.es/cima/dochtml/ft/82081/FT\\_82081.html](https://cima.aemps.es/cima/dochtml/ft/82081/FT_82081.html)
21. [https://www.adacap.com/sites/novartis\\_adacap/files/AAACHoline\\_CH\\_RCP\\_FR\\_AIPS\\_160912.pdf](https://www.adacap.com/sites/novartis_adacap/files/AAACHoline_CH_RCP_FR_AIPS_160912.pdf)
22. [https://www.adacap.com/sites/novartis\\_adacap/files/AAACHoline\\_CH\\_RCP\\_DE\\_AIPS\\_160912.pdf](https://www.adacap.com/sites/novartis_adacap/files/AAACHoline_CH_RCP_DE_AIPS_160912.pdf)
23. [https://www.adacap.com/sites/novartis\\_adacap/files/it-aaacholine-222-mbq-ml-fluorometil.pdf](https://www.adacap.com/sites/novartis_adacap/files/it-aaacholine-222-mbq-ml-fluorometil.pdf)
24. [https://www.adacap.com/sites/novartis\\_adacap/files/CT\\_GLUSCAN.pdf](https://www.adacap.com/sites/novartis_adacap/files/CT_GLUSCAN.pdf)
25. [https://www.adacap.com/sites/novartis\\_adacap/files/SPC-Gluscan-April-2024.pdf](https://www.adacap.com/sites/novartis_adacap/files/SPC-Gluscan-April-2024.pdf)
26. [https://www.adacap.com/sites/novartis\\_adacap/files/PIL-Gluscan-April-2024.pdf](https://www.adacap.com/sites/novartis_adacap/files/PIL-Gluscan-April-2024.pdf)
27. [https://www.adacap.com/sites/novartis\\_adacap/files/Gluscan-FI-Dezember-2022.pdf](https://www.adacap.com/sites/novartis_adacap/files/Gluscan-FI-Dezember-2022.pdf)
28. [https://www.adacap.com/sites/novartis\\_adacap/files/Gluscan-GI-Dezember-2022-1.pdf](https://www.adacap.com/sites/novartis_adacap/files/Gluscan-GI-Dezember-2022-1.pdf)
29. [https://www.adacap.com/sites/novartis\\_adacap/files/GLUSCAN\\_RCP\\_JAN23-1.pdf](https://www.adacap.com/sites/novartis_adacap/files/GLUSCAN_RCP_JAN23-1.pdf)
30. [https://www.adacap.com/sites/novartis\\_adacap/files/RCM\\_Gluscan.pdf](https://www.adacap.com/sites/novartis_adacap/files/RCM_Gluscan.pdf)
31. [https://www.adacap.com/sites/novartis\\_adacap/files/FI-Gluscan-April-2024.pdf](https://www.adacap.com/sites/novartis_adacap/files/FI-Gluscan-April-2024.pdf)
32. [https://cima.aemps.es/cima/dochtml/ft/68016/FT\\_68016.html](https://cima.aemps.es/cima/dochtml/ft/68016/FT_68016.html)
33. [https://cima.aemps.es/cima/pdfs/ft/81346/FT\\_81346.pdf](https://cima.aemps.es/cima/pdfs/ft/81346/FT_81346.pdf)
34. [https://www.adacap.com/sites/novartis\\_adacap/files/GLUSCAN\\_CH\\_RCP\\_FR\\_AIPS\\_Vs11\\_191024\\_FR.pdf](https://www.adacap.com/sites/novartis_adacap/files/GLUSCAN_CH_RCP_FR_AIPS_Vs11_191024_FR.pdf)
35. [https://www.adacap.com/sites/novartis\\_adacap/files/GLUSCAN\\_CH\\_RCP\\_DE\\_AIPS\\_Vs5\\_191024\\_DE.pdf](https://www.adacap.com/sites/novartis_adacap/files/GLUSCAN_CH_RCP_DE_AIPS_Vs5_191024_DE.pdf)
36. [https://www.adacap.com/sites/novartis\\_adacap/files/GLUSCAN\\_CH\\_RCP\\_IT\\_AIPS\\_Vs4\\_191024\\_IT.pdf](https://www.adacap.com/sites/novartis_adacap/files/GLUSCAN_CH_RCP_IT_AIPS_Vs4_191024_IT.pdf)